​

Arcutis Biotherapeutics Ownership | Who Owns Arcutis Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Arcutis Biotherapeutics Ownership Summary


Arcutis Biotherapeutics is owned by 114.26% institutional investors, 1.80% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 14.69% of ARQT shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.44% of its assets in Arcutis Biotherapeutics shares.

ARQT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArcutis Biotherapeutics114.26%1.80%-16.06%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de19.17M14.69%$506.69M
Suvretta capital management12.44M9.61%$326.10M
Blackrock8.62M7.76%$80.19M
Frazier life sciences management9.87M7.63%$258.91M
Rubric capital management lp8.27M6.39%$216.88M
State street7.72M5.91%$204.00M
Vanguard group7.25M5.68%$210.65M
Polar capital6.61M5.11%$173.23M
Ubs group5.53M4.24%$146.24M
Morgan stanley5.30M4.06%$139.99M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pivotal bioventure partners investment advisor1.01M10.58%$26.65M
Suvretta capital management12.44M5.96%$326.10M
Frazier life sciences management9.87M5.64%$258.91M
Ally bridge group (ny)233.22K2.68%$4.40M
Rubric capital management lp8.27M1.99%$216.88M
Privium fund management b.v.333.19K1.71%$8.81M
Pavaki capital management187.00K1.68%$4.94M
Fishman jay a ltd/mi597.12K1.27%$15.78M
1492 capital management113.46K1.01%$3.00M
Orbimed advisors2.04M1.00%$53.54M

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de19.17M0.01%8.63M
Ubs group5.53M0.02%2.20M
Orbimed advisors2.04M1.00%2.04M
Blackrock8.62M0.00%1.96M
State street7.72M0.01%1.90M

Top Sellers

HolderShares% AssetsChange
Gilder gagnon howe1.31M0.36%-2.99M
Paradigm biocapital advisors lp---1.47M
Perceptive advisors---1.36M
Driehaus capital management878.43K0.13%-1.35M
Braidwell lp---1.30M

New Positions

HolderShares% AssetsChangeValue
Orbimed advisors2.04M1.00%2.04M$53.54M
Simplify asset management865.86K0.37%865.86K$22.88M
Public sector pension investment board774.31K0.04%774.31K$20.33M
Norges bank392.30K0.00%392.30K$10.29M
Longaeva partners344.80K0.20%344.80K$9.04M

Sold Out

HolderChange
Twin peaks wealth advisors-7.00
Massmutual trust co fsb/adv-7.00
National bank of canada /fi/-12.00
Advisory services network-19.00
Nelson, van denburg & campbell wealth management group-22.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20263037.07%149,136,76112.56%1141.11%19241.18%69-33.65%
Jun 30, 20262800.72%132,367,241-0.02%1020.98%137-5.52%10114.77%
Mar 31, 2026270-6.90%129,847,5480.58%1021.00%141-19.43%8611.69%
Dec 31, 2025127-48.79%34,362,908-72.69%260.27%72-40.98%38-54.22%
Sep 30, 202587-63.14%29,200,444-76.92%220.23%44-63.64%25-62.69%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF6.88M5.44%-5.71K
Polar Capital Biotech S Inc6.26M4.98%-
Vanguard US Total Market Shares ETF3.59M3.03%492.10K
Vanguard MStar Total Stk Mkt Idx Invest3.59M2.85%13.03K
Vanguard Total Stock Mkt Idx Inv3.57M2.85%33.08K
Vanguard Morn Total Stk Mkt Idx Investor3.57M2.85%33.08K
State Street® SPDR® S&P® Biotech ETF3.24M2.56%84.83K
iShares Russell 2000 ETF2.90M2.29%-
Jennison Health Sciences Equity2.27M1.90%-
PGIM Jennison Health Sciences Z2.27M1.89%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 04, 2026Matsuda Masaru EVP, Chief Legal OfficerSell$1.37M
Nov 02, 2026Matsuda Masaru EVP, Chief Legal OfficerSell$38.84K
Nov 02, 2026Burnett Patrick EVP, Chief Medical OfficerSell$30.05K
Nov 02, 2026Watanabe Todd See RemarksSell$139.47K
Oct 15, 2026Welgus Howard G.-Sell$127.33K

Insider Transactions Trends


DateBuySell
2026 Q4-5
2026 Q3-13
2026 Q2-12
2026 Q1-26
2025 Q4-32

ARQT Ownership FAQ


Who Owns Arcutis Biotherapeutics?

Arcutis Biotherapeutics shareholders are primarily institutional investors at 114.26%, followed by 1.80% insiders and -16.06% retail investors. The average institutional ownership in Arcutis Biotherapeutics's industry, Biotech Stocks , is 181.71%, which Arcutis Biotherapeutics falls below.

Who owns the most shares of Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s largest shareholders are Blackrock funding, inc. /de (19.17M shares, 14.69%), Suvretta capital management (12.44M shares, 9.61%), and Blackrock (8.62M shares, 7.76%). Together, they hold 32.07% of Arcutis Biotherapeutics’s total shares outstanding.

Does Blackrock own Arcutis Biotherapeutics?

Yes, BlackRock owns 7.76% of Arcutis Biotherapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 80.19M$. In the last quarter, BlackRock increased its holdings by 1.96M shares, a 29.49% change.

Who is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 10.58% of its assets in 1.01M Arcutis Biotherapeutics shares, valued at 26.65M$.

Who is the top mutual fund holder of Arcutis Biotherapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arcutis Biotherapeutics shares, with 5.44% of its total shares outstanding invested in 6.88M Arcutis Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools